Author:
Althobaiti Yusuf S.,Almutairi Farooq M.,Alshehri Fahad S.,Altowairqi Ebtehal,Marghalani Aliyah M.,Alghorabi Amal A.,Alsanie Walaa F.,Gaber Ahmed,Alsaab Hashem O.,Almalki Atiah H.,Hakami Alqassem Y.,Alkhalifa Turki,Almalki Ahmad D.,Hardy Ana M. G.,Shah Zahoor A.
Abstract
AbstractThere has been an increase in cases of drug addiction and prescription drug abuse worldwide. Recently, pregabalin abuse has been a focus for many healthcare agencies, as highlighted by epidemiological studies. We previously evaluated the possibility of pregabalin abuse using the conditioned place preference (CPP) paradigm. We observed that a 60 mg/kg dose could induce CPP in mice and that pregabalin-rewarding properties were mediated through glutamate neurotransmission. Notably, the dopaminergic reward circuitry is also known to play a crucial role in medication-seeking behavior. Therefore, this study aimed to explore the possible involvement of dopaminergic receptor-1 in pregabalin-induced CPP. Mice were randomly allocated to receive saline or the dopamine-1 receptor antagonist SKF-83566 (0.03 mg/kg, intraperitoneal). After 30 min, the mice received either saline or pregabalin (60 mg/kg) during the conditioning phase. Among the control groups that received saline or SKF-83566, the time spent in the two conditioning chambers was not significantly altered. However, among the pregabalin-treated group, there was a marked increase in the time spent in the drug-paired chamber compared to the time spent in the vehicle-paired chamber. Notably, blocking dopamine-1 receptors with SKF-83566 completely prevented pregabalin-induced place preference, thus demonstrating the engagement of the dopaminergic system in pregabalin-induced reward-related behavior.
Publisher
Springer Science and Business Media LLC
Reference110 articles.
1. DuPont, R. L. Prescription drug abuse: An epidemic dilemma. J. Psychoactive Drugs 42, 127–132 (2010).
2. Piskorska, B., Miziak, B., Czuczwar, S. J. & Borowicz, K. K. Safety issues around misuse of antiepileptics. Expert Opin. Drug Saf. 12, 647–657 (2013).
3. Loftus, H. & Wright, A. Potential misuse of pregabalin and gabapentin. BMJ 348, g1290 (2014).
4. European Monitoring Centre for Drugs and Drug Addiction, E. P. O. E. European Drug Report 2014: Trends and developments (2014).
5. Spence, D. Bad medicine: Gabapentin and pregabalin. BMJ Br. Med. J. 347, f6747. https://doi.org/10.1136/bmj.f6747 (2013).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献